EF
ALNY icon

Empowered Funds’s Alnylam Pharmaceuticals ALNY Stock Holding History

Empowered Funds’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,179
Closed -$280K – 522
2022
Q4 		$280K Buy
+1,179
New +$251K 0.02% 401

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Empowered Funds's ALNY Position: Q1 2026 in Review

Empowered Funds reduced its Alnylam Pharmaceuticals (ALNY) stake by 72% in Q1 2026, selling an estimated $4.77M and leaving 5,410 shares worth $1.79M. The position accounts for 0.01% of the portfolio, ranked #1160.

Empowered Funds first reported a position in ALNY in Q3 2022 and has held it in 14 quarters since. The position peaked at $7.73M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Empowered Funds held 5,410 shares of Alnylam Pharmaceuticals worth $1.79M as of Q1 2026.
  • Empowered Funds sold 14,021 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $4.77M.
  • Alnylam Pharmaceuticals made up 0.01% of Empowered Funds's portfolio in Q1 2026, its #1160 holding.
  • Empowered Funds first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 14 quarters since.
  • Empowered Funds's Alnylam Pharmaceuticals position peaked at $7.73M in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.